Hadassah

Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Dec 15 2017

The Pediatric Intensive Care Unit (PICU) at Hadassah Hospital

An intimate video tour of the Pediatric Intensive Care Unit (PICU) at Hadassah Hospital highlights the miraculous recoveries of children given a second chance, with firsthand accounts from their grateful parents and their extraordinary doctors and nurses.

READ MORE ›
alt_text

Tuesday, Dec 12 2017

Hadassah Mount Scopus Rehab Gets Boost at Hadassah International Israel Gala Dinner

More than a thousand Israelis expressed their support for the eagerly anticipated new Hadassah Hospital Mount Scopus rehabilitation center for wounded soldiers and terror survivors at a gala event sponsored by Hadassah International Israel at the David International Hotel in Tel Aviv.

READ MORE ›
alt_text

Tuesday, Dec 12 2017

Older People Who Get Out Live Longer

A study led by Hadassah Physician Dr. Jeremy Michael Jacobs, Chair of the Hadassah Medical Organization’s Geriatric and Rehabilitation Complex, reveals that individuals between the ages of 70 and 90 who leave the house daily have a lower risk of mortality, independent of social, functional or medical status.

READ MORE ›
alt_text

Monday, Dec 11 2017

Twin boy Saved by Hadassah Experts and Cutting-Edge Technology

Simcha and his twin sister, Sarah, were born to a Jerusalem couple in their early forties, after years of hoping for children.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More